Screening 12 - Extended Combined Test
in the 12th-14th week of pregnancy
Goals
- Probability calculation for trisomy 13, 18, and 21 as well as pre-eclampsia (alternative term for toxemia of pregnancy)
- Detection of any severe malformations
Cost of the examination
€250
The Combined Test calculates the probability of trisomy 13, 18, and 21, as well as pre-eclampsia, and detects any severe malformations. It combines the results of the nuchal translucency measurement with other ultrasound markers, a blood flow measurement, and a maternal blood test. The detection rate for Down syndrome is 90%.
In the Combined Test, the blood sample is taken and blood pressure is measured first, after which two placental hormones from the mother's blood are analyzed. Meanwhile, the ultrasound scan is performed. The results of the ultrasound are combined with the blood results and yield a probability for Down's syndrome, trisomy 13 and trisomy 18, as well as for pre-eclampsia.
Precise risk calculation and rapid reassurance through the Combined Test
The Combined Test calculates the probability of Down syndrome (trisomy 21), trisomy 13, and trisomy 18 based on several factors. These factors include the results of the first-trimester ultrasound (measuring nuchal translucency, the nasal bone, and blood flow), a maternal blood test, and the age of the pregnant woman.
During the blood test, we measure the serum concentration of fbhCG, PAPP-A and – as one of only a few institutes in Austria – additionally the placental growth factor (PlGF).
During the first-trimester ultrasound, an early examination of the fetal anatomy is also performed to rule out any potential severe malformations.
As part of the combined test, we also screen for the probability of pre-eclampsia (commonly referred to as toxemia of pregnancy). This condition can lead to premature birth and other pregnancy complications. The main symptoms of pre-eclampsia are high blood pressure and protein in the urine. To determine the risk, the expecting mother's blood pressure, placental blood flow, and biomarkers in her blood are checked. In cases of elevated risk, a low-side-effect therapy can reduce the occurrence of severe pre-eclampsia by more than 80 percent.
If the child's position allows, we will gladly produce a 3D ultrasound image upon request during the examination.
- Since the blood test is performed directly in our prenatal center, we can inform you about the results of the Screening 12 in a detailed consultation shortly after the examination.
- Your ultrasound images are immediately available to you digitally.
Investigation Timeline
Our prenatal center is equipped with its own laboratory. This makes it possible to carry out examinations entirely in our facility and to inform you of the results very quickly.
Book an appointment
Our prenatal center is equipped with its own laboratory. This allows us to perform all examinations entirely in-house.
Cost of the examination
€250Q&A
The combined test is available to women of any age. The combined test can determine the risk of chromosomal abnormalities, specifically Trisomy 21 (Down syndrome) as well as Trisomy 13 or 18. This risk increases with age. During pregnancy, a combined test can be performed between 11 weeks + 3 days and 13 weeks + 6 days of gestation.
The Combined Test is possible between 11+3 and 13+6 weeks of pregnancy. Ideally, the test is performed between 12+0 and 13+0 weeks of pregnancy. The crown-rump length during this period measures between 45 and 84 mm. Before and after this window, measurement of the nuchal translucency is not possible.
The entire combined test, consisting of a blood test and an ultrasound scan, usually takes 1.5 hours. During this time, the blood collection, an ultrasound scan and the discussion of the results take place. Results are available immediately after the combined test.
A result for the Combined Test is available immediately after the Combined Test examination. The result will be discussed in detail during a consultation. At the end, you will receive a printout of the findings.
The evaluation of the result takes place immediately after the Combined Test and the associated blood draw. The analysis takes about 1.5 hours, after which the result is available.
The nuchal translucency scan (first-trimester screening) is an important part of the combined test. In combination with a blood test of the pregnant woman, the combined test calculates the probability of Down syndrome (trisomy 21), trisomy 13, and 18.
At the prenatal center, the Combined Test costs €250. For twin pregnancies, the Combined Test costs €300.
Preeclampsia (also known as toxemia of pregnancy or EPH gestosis) is a disease affecting pregnant women. It usually occurs after the 20th week of pregnancy and is characterized by high blood pressure and other symptoms such as protein excretion in the urine, elevated liver enzymes, and growth disorders of the unborn child. In the event of an increased risk, the daily intake of 150mg of Thrombo ASS can significantly reduce the risk of preeclampsia.
The probability of preeclampsia (also known as pregnancy-induced hypertension or toxemia) is determined using a preeclampsia screening. This screening is performed in conjunction with a Combined Test at no additional cost or extra time.
Preeclampsia screening is possible between weeks 11+3 and 13+6 of pregnancy. That is at the same time as the combined test.
The cost of the pre-eclampsia screening is included in the combined test.